These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 8740246)

  • 1. Yawning behavior for preclinical drug evaluation.
    Furukawa T
    Methods Find Exp Clin Pharmacol; 1996 Mar; 18(2):141-55. PubMed ID: 8740246
    [No Abstract]   [Full Text] [Related]  

  • 2. Penile erection and yawning induced by dopamine D2-like receptor agonists in rats: influence of strain and contribution of dopamine D2, but not D3 and D4 receptors.
    Depoortère R; Bardin L; Rodrigues M; Abrial E; Aliaga M; Newman-Tancredi A
    Behav Pharmacol; 2009 Jul; 20(4):303-11. PubMed ID: 19584712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The novel antidyskinetic drug sarizotan elicits different functional responses at human D2-like dopamine receptors.
    Kuzhikandathil EV; Bartoszyk GD
    Neuropharmacology; 2006 Sep; 51(4):873-84. PubMed ID: 16844149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiparkinson therapeutic potencies correlate with their affinities at dopamine D2(High) receptors.
    Seeman P
    Synapse; 2007 Dec; 61(12):1013-8. PubMed ID: 17853435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacology of levodopa-induced dyskinesia in parkinsonian patients.
    Rascol O; Brefel-Courbon C; Descombes S; Montastruc JL
    Adv Neurol; 1999; 80():485-90. PubMed ID: 10410760
    [No Abstract]   [Full Text] [Related]  

  • 6. Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors.
    Brocco M; Dekeyne A; Papp M; Millan MJ
    Behav Pharmacol; 2006 Nov; 17(7):559-72. PubMed ID: 17021388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Yawning in Parkinson's disease.
    O'Sullivan JD; Lees AJ; Hughes AJ
    Neurology; 1999 Jan; 52(2):428. PubMed ID: 9932982
    [No Abstract]   [Full Text] [Related]  

  • 8. Yawning in Parkinson's disease.
    Evidente VG; Hardy KG
    Neurology; 1999 Jan; 52(2):428. PubMed ID: 9932981
    [No Abstract]   [Full Text] [Related]  

  • 9. Yawning in Parkinson's disease.
    Colosimo C; Pontieri FE
    Neurology; 1999 Jan; 52(2):428. PubMed ID: 9932980
    [No Abstract]   [Full Text] [Related]  

  • 10. CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine.
    Aklillu E; Kalow W; Endrenyi L; Harper P; Miura J; Ozdemir V
    Pharmacogenet Genomics; 2007 Nov; 17(11):989-93. PubMed ID: 18075468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BP-897 Bioprojet.
    Preti A
    Curr Opin Investig Drugs; 2000 Sep; 1(1):110-5. PubMed ID: 11249586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medications for Parkinson's disease.
    Whitney CM
    Neurologist; 2007 Nov; 13(6):387-8. PubMed ID: 18090719
    [No Abstract]   [Full Text] [Related]  

  • 13. The role of catecholamines in the prolactin release induced by salsolinol.
    Székács D; Bodnár I; Vizi ES; Nagy GM; Fekete MI
    Neurochem Int; 2007 Oct; 51(5):319-22. PubMed ID: 17764787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Markers of D(2) and D(3) receptor activity in vivo: PET scan and prolactin.
    Thomasson-Perret N; Pénélaud PF; Théron D; Gouttefangeas S; Mocaër E
    Therapie; 2008; 63(3):237-42. PubMed ID: 18718212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine.
    Morissette M; Goulet M; Calon F; Falardeau P; Blanchet PJ; Bédard PJ; Di Paolo T
    Mol Pharmacol; 1996 Nov; 50(5):1073-9. PubMed ID: 8913337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sex steroids are involved in the regulation of gonadotropin-releasing hormone and dopamine D2 receptors in female tilapia pituitary.
    Levavi-Sivan B; Biran J; Fireman E
    Biol Reprod; 2006 Oct; 75(4):642-50. PubMed ID: 16807382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of adulthood nicotine treatment on D2-mediated behavior and neurotrophins of rats neonatally treated with quinpirole.
    Brown RW; Perna MK; Schaefer TL; Williams MT
    Synapse; 2006 Apr; 59(5):253-9. PubMed ID: 16408261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurement of dopamine D2-like receptors in postmortem CNS and pituitary: differential regional changes in schizophrenia.
    Dean B; Pavey G; Scarr E; Goeringer K; Copolov DL
    Life Sci; 2004 May; 74(25):3115-31. PubMed ID: 15081577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiparkinson concentrations of pramipexole and PHNO occupy dopamine D2(high) and D3(high) receptors.
    Seeman P; Ko F; Willeit M; McCormick P; Ginovart N
    Synapse; 2005 Nov; 58(2):122-8. PubMed ID: 16088951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Toxic and adverse neurological effects of anti-parkinsonian drugs].
    Sunohara N
    Ryoikibetsu Shokogun Shirizu; 1999; (27 Pt 2):527-31. PubMed ID: 10434715
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.